AstraZeneca (NASDAQ:AZN) Shares Unloaded Rep. Val T. Hoyle

Key Points

• Representative Val T. Hoyle sold between $1,001 and $15,000 in AstraZeneca shares on September 23rd, as disclosed in a filing on October 10th.
• AstraZeneca's shares were trading down 0.6% at $84.53, with a market cap of $262.16 billion and a price-to-earnings ratio of 31.78.
• The company recently announced a semi-annual dividend of $0.505 per share, representing a dividend yield of 200.0% with a payout ratio of 37.97%.

Representative Val T. Hoyle (D-Oregon) recently sold shares of AstraZeneca PLC NASDAQ: AZN. In a filing disclosed on October 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in AstraZeneca stock on September 23rd. The trade occurred in the Representative's "FIDELITY ROLLOVER IRA" account.

Representative Val T. Hoyle also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Marriott International NASDAQ: MAR on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Transdigm Group NYSE: TDG on 9/23/2025.
• Sold $1,001 - $15,000 in shares of H&R Block NYSE: HRB on 9/23/2025.
• Sold $1,001 - $15,000 in shares of NIKE NYSE: NKE on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Bank of New York Mellon NYSE: BK on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Cisco Systems NASDAQ: CSCO on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Capital One Financial NYSE: COF on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Pentair NYSE: PNR on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Heico NYSE: HEI.A on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Target NYSE: TGT on 9/23/2025.

AstraZeneca Trading Down 0.6%

Shares of NASDAQ AZN opened at $84.53 on Friday. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $86.57. The company has a market cap of $262.16 billion, a price-to-earnings ratio of 31.78, a P/E/G ratio of 1.56 and a beta of 0.36. The business has a fifty day simple moving average of $79.18 and a 200-day simple moving average of $73.45.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.09. The firm had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business's revenue for the quarter was up 16.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.24 EPS. Sell-side analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Monday, September 8th. Stockholders of record on Friday, August 8th were given a dividend of $0.505 per share. The ex-dividend date of this dividend was Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca's payout ratio is 37.97%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on AZN. Weiss Ratings reaffirmed a "buy (b)" rating on shares of AstraZeneca in a research note on Wednesday. Berenberg Bank set a $97.00 target price on AstraZeneca in a research report on Wednesday, July 9th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $86.00.

Hedge Funds Weigh In On AstraZeneca

Several institutional investors and hedge funds have recently modified their holdings of the stock. NewSquare Capital LLC raised its holdings in shares of AstraZeneca by 149.3% during the second quarter. NewSquare Capital LLC now owns 364 shares of the company's stock worth $25,000 after acquiring an additional 218 shares in the last quarter. Larson Financial Group LLC increased its position in AstraZeneca by 297.9% in the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company's stock worth $28,000 after purchasing an additional 289 shares during the last quarter. Richardson Financial Services Inc. raised its stake in shares of AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company's stock worth $28,000 after purchasing an additional 149 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of AstraZeneca during the 1st quarter valued at about $29,000. Finally, Costello Asset Management INC bought a new stake in shares of AstraZeneca in the 1st quarter valued at approximately $29,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Hoyle

Val Hoyle (Democratic Party) is a member of the U.S. House, representing Oregon's 4th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. Hoyle (Democratic Party) is running for re-election to the U.S. House to represent Oregon's 4th Congressional District. She declared candidacy for the 2026 election. Val Hoyle was born in California and lives in Springfield, Oregon. Hoyle graduated from Merrimack High School. She earned a B.A. in political science from Emmanuel College in 1992. Her career experience includes working as a director at United Way of Lane County, a policy fellow at Wayne Morse Center for Law and Politics, and a commissioner at the Oregon Bureau of Labor and Industries. Hoyle has also worked in domestic and international sales, as well as manufacturing distribution.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.